Chinese firms invest heavily in CAR-T cell therapy research

19 August 2021
china_big

Research from industry analyst GlobalData shows that domestic drug developers in China are leading the way in CAR-T cell therapy trials, with 337 company-sponsored studies underway.

In addition, the country’s overall focus within oncology research is increasing rapidly, with China’s first approval for a treatment of this kind coming in June 2021.

Only the second country in Asia to grant approval for a CAR-T cell therapy, China’s medicines regulator granted approval to Yescarta (axicabtagene ciloleucel), from Gilead’s (Nasdaq: GILD) Chinese subsidiary, FosunKite.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology